Spyre Therapeutics Inc.
SYRE
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.44B
Close$
$0.25
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.44 Billion |
|---|---|
| Enterprise Value | $4.34 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.98 |
| Beta | 3.13 |
| Outstanding Shares | 346,045,000 |
Return
| Return on Equity | -26.75% |
|---|---|
| Return on Assets | -23.49% |
| Return on Invested Capital | -28.94% |
Valuation & Multiples
| P/E Ratio | -141.75 |
|---|---|
| PEG | -261.9 |
| Price to Sales | - |
| Price to Book Ratio | 73.52 |
| Enterprise Value to Revenue | 47.98 |
| Enterprise Value to EBIT | -22.11 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$70.87 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.70
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0876▲ 0.86% |
|---|---|
| Total Calls | 324,200▼ 21.67% |
| Total Puts | 28,400▼ 13.15% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.88%▼ 84.19% |
|---|---|
| Total Invested | $4.16B▲ 56.93% |
| Investors Holding | 200▲ 44.00% |
ESG Score
No data
About Spyre Therapeutics Inc.
83 employeesaeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant...